Paris Vail
YOU?
Author Swipe
View article: Supplementary Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Supplementary Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition Open
Supplementary Table 1
View article: Supplemental Figures from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer
Supplemental Figures from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer Open
Supplemental Figures S1-S8
View article: Supplemental Data 1 from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer
Supplemental Data 1 from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer Open
Full list of genes in correlation analysis for Figure 3. Includes correlation coefficients and z-score values.
View article: Supplementary Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Supplementary Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition Open
Supplementary Table 2
View article: Supplemental Figures 1-5 from Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers
Supplemental Figures 1-5 from Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers Open
Supplemental Figure 1: Clinical and pathological information for the cohort employed in the present study. Supplemental Figure 2: (A) Specific genes that define the immunological signatures as indicated. (B) Application of immunological si…
View article: Supplemental Figure Legends from Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers
Supplemental Figure Legends from Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers Open
Supplemental Figure Legends
View article: Supplemental Figures 1-5 from Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers
Supplemental Figures 1-5 from Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers Open
Supplemental Figure 1: Clinical and pathological information for the cohort employed in the present study. Supplemental Figure 2: (A) Specific genes that define the immunological signatures as indicated. (B) Application of immunological si…
View article: Supplemental Figure Legends from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer
Supplemental Figure Legends from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer Open
Supplemental Figure Legends
View article: Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition Open
Intrinsic or acquired resistance to clinically approved CDK4/6 inhibitors has emerged as a major obstacle that hinders their utility beyond ER+ breast cancer. In this study, CDK4/6-dependent and -resistant models were employed to identify …
View article: Supplemental Data 2 from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer
Supplemental Data 2 from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer Open
Full list of agents used in drug screen described in Figure 4.
View article: Supplementary Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Supplementary Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition Open
Supplementary Table 1
View article: Supplementary Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Supplementary Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition Open
Supplementary information
View article: Supplemental Figures from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer
Supplemental Figures from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer Open
Supplemental Figures S1-S8
View article: Data from Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers
Data from Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers Open
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is associated with an immunosuppressive milieu that supports immune system evasion and disease progression. Here, we interrogated genetic, stromal, and immunologic features of PDAC to deline…
View article: Data from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer
Data from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer Open
Purpose:Cancer cells often have deficiencies in cell-cycle control mechanisms and could be dependent on specific cell-cycle checkpoints to maintain viability. Because of the documented role of KRAS in driving replication stress, we targete…
View article: Supplementary Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Supplementary Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition Open
Supplementary Table 2
View article: Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition Open
Intrinsic or acquired resistance to clinically approved CDK4/6 inhibitors has emerged as a major obstacle that hinders their utility beyond ER+ breast cancer. In this study, CDK4/6-dependent and -resistant models were employed to identify …
View article: Data from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer
Data from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer Open
Purpose:Cancer cells often have deficiencies in cell-cycle control mechanisms and could be dependent on specific cell-cycle checkpoints to maintain viability. Because of the documented role of KRAS in driving replication stress, we targete…
View article: Supplementary Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Supplementary Data from Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition Open
Supplementary information
View article: Supplemental Data 1 from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer
Supplemental Data 1 from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer Open
Full list of genes in correlation analysis for Figure 3. Includes correlation coefficients and z-score values.
View article: Supplemental Figure Legends from Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers
Supplemental Figure Legends from Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers Open
Supplemental Figure Legends
View article: Supplemental Data 2 from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer
Supplemental Data 2 from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer Open
Full list of agents used in drug screen described in Figure 4.
View article: Data from Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers
Data from Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers Open
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is associated with an immunosuppressive milieu that supports immune system evasion and disease progression. Here, we interrogated genetic, stromal, and immunologic features of PDAC to deline…
View article: Supplemental Figure Legends from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer
Supplemental Figure Legends from Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer Open
Supplemental Figure Legends
View article: Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition
Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition Open
Intrinsic or acquired resistance to clinically approved CDK4/6 inhibitors has emerged as a major obstacle that hinders their utility beyond ER+ breast cancer. In this study, CDK4/6-dependent and -resistant models were employed to identify …
View article: A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy Open
Purpose: Metastatic pancreatic adenocarcinoma (mPC) has a poor prognosis. CDK4/6 is often deregulated in mPC due to CDKN2A loss, resulting in the loss of p16INK4a that inhibits CDK4/6. CDK4/6 inhibitor monotherapy is ineffective due to RAS…
View article: Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer
Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer Open
Objective This study exploits the intersection between molecular-targeted therapies and immune-checkpoint inhibition to define new means to treat pancreatic cancer. Design Patient-derived cell lines and xenograft models were used to define…
View article: Targeting dual signaling pathways in concert with immune checkpoints for the treatment of pancreatic cancer
Targeting dual signaling pathways in concert with immune checkpoints for the treatment of pancreatic cancer Open
Pancreatic cancer harbors a poor prognosis due to the lack of effective systemic therapies. Here we interrogated means to target key effector pathways down-stream from KRAS. We found that combination treatment with MEK and CDK4/6 inhibitor…